...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study
【24h】

Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study

机译：Saroglitazar在非糖尿病非酒精性脂肪肝病患者的作用：回顾性观测研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly encountered problem which affects one third of the general population. Saroglitazar, a Peroxisome Proliferator Activated Receptor (PPAR) alpha α and gamma γ agonist has been recently approved for treatment of NAFLD.Aim: To assess the efficacy of saroglitazar in non diabetic NAFLD patients.Materials and Methods: It was a retrospective observational study, conducted from October 2020 to March 2021 on 45 non diabetic NAFLD patients, at a tertiary care centre in north-eastern India. Liver enzymes, liver fibrosis and liver fat content were compared before and after receiving saroglitazar for 24 weeks. Multiple regression analysis was used to assess percent change in Alanine Transaminase (ALT), Aspartate Transaminase (AST), ALP, bilirubin, Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP). The p-values <0.05 were considered as statistically significant.Results: Mean age of the study population was 46±8.20 years, and there were 24 males and 21 females. Reduction in liver enzymes like Alanine Transaminase (ALT) and Aspartate Transaminase (AST) and fibroscan parameters like Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) were seen. Mean values of ALT and AST at pretreatment status were 85.52±17.12 U/L and 70.02±19.10 U/L, and after treatment were 40.20±12.11 U/L and 37.32±8.31 U/L, respectively (p-value <0.0001 for both ALT and AST). Pretreatment and post treatment mean values for LSM and CAP were 8.11±2.18 kPa (kilopascal), 365.84±56.22 d/m (decibel/meter) and 7.20±1.80 kPa, 345.21±35.22 d/m, respectively (p-value=0.021 for LSM and 0.036 for CAP).Conclusion: Twenty four weeks saroglitazar was effective in treatment of non diabetic NAFLD. It not only reduces hepatocellular inflammation, but also liver fibrosis and liver fat.
机译：非酒精脂肪肝病（NAFLD）是一种常见的问题，影响一般人群的三分之一。 Saroglitazar，过氧化物酶促增殖物激活受体（PPAR）αα和γγ激动剂已被批准用于NAFLD.aim：评估纱曲霉在非糖尿病NAFLD患者中的疗效。材料和方法：这是一个回顾性观察研究，从10月20日到45名非糖尿病NAFLD患者于3月2021日开始，在印度东北部的第三次护理中心。在接受Saroglitazar 24周之前和之后比较肝酶，肝纤维化和肝脂肪含量。使用多元回归分析来评估丙氨酸转氨酶（ALT），天冬氨酸转氨酶（AST），ALP，胆红素，肝刚度测量（LSM）和受控衰减参数（盖子）的百分比变化。 P值<0.05被认为是统计学上的显着性。结果：研究人口的平均年龄为46±8.20岁，有24名男性和21个女性。看到肝脏转氨酶（ALT）和天冬氨酸转氨酶（AST）和纤维载参数等肝脏酶等肝酶及纤维血管参数等。 Alt和AST在预处理状态下的平均值为85.52±17.12 U / L和70.02±19.10 U / L，并且处理后分别为40.20±12.11 U / L和37.32±8.31 U / L（P值<0.0001 alt和ast）。 LSM和帽的预处理和后处理平均值为8.11±2.18 KPA（千冈），365.84±56.22d / m（分贝/仪表）和7.20±1.80 kPa，分别为345.21±35.22 d / m（p值= 0.021对于LSM和0.036的帽）。结论：二十四周Saroglitazar对治疗非糖尿病NAFLD有效。它不仅降低了肝细胞炎症，而且还减少了肝纤维化和肝脏脂肪。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号